270 related articles for article (PubMed ID: 36911944)
1. Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG).
Finkel RS; Darras BT; Mendell JR; Day JW; Kuntz NL; Connolly AM; Zaidman CM; Crawford TO; Butterfield RJ; Shieh PB; Tennekoon G; Brandsema JF; Iannaccone ST; Shoffner J; Kavanagh S; Macek TA; Tauscher-Wisniewski S
J Neuromuscul Dis; 2023; 10(3):389-404. PubMed ID: 36911944
[TBL] [Abstract][Full Text] [Related]
2. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
Day JW; Finkel RS; Chiriboga CA; Connolly AM; Crawford TO; Darras BT; Iannaccone ST; Kuntz NL; Peña LDM; Shieh PB; Smith EC; Kwon JM; Zaidman CM; Schultz M; Feltner DE; Tauscher-Wisniewski S; Ouyang H; Chand DH; Sproule DM; Macek TA; Mendell JR
Lancet Neurol; 2021 Apr; 20(4):284-293. PubMed ID: 33743238
[TBL] [Abstract][Full Text] [Related]
3. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial.
Mercuri E; Muntoni F; Baranello G; Masson R; Boespflug-Tanguy O; Bruno C; Corti S; Daron A; Deconinck N; Servais L; Straub V; Ouyang H; Chand D; Tauscher-Wisniewski S; Mendonca N; Lavrov A;
Lancet Neurol; 2021 Oct; 20(10):832-841. PubMed ID: 34536405
[TBL] [Abstract][Full Text] [Related]
4. From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1.
Al-Zaidy SA; Mendell JR
Pediatr Neurol; 2019 Nov; 100():3-11. PubMed ID: 31371124
[TBL] [Abstract][Full Text] [Related]
5. Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy.
Blair HA
CNS Drugs; 2022 Sep; 36(9):995-1005. PubMed ID: 35960489
[TBL] [Abstract][Full Text] [Related]
6. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
[TBL] [Abstract][Full Text] [Related]
7. Safety of Onasemnogene Abeparvovec for Patients With Spinal Muscular Atrophy 8.5 kg or Heavier in a Global Managed Access Program.
Chand DH; Mitchell S; Sun R; LaMarca N; Reyna SP; Sutter T
Pediatr Neurol; 2022 Jul; 132():27-32. PubMed ID: 35605311
[TBL] [Abstract][Full Text] [Related]
8. Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry.
Servais L; Day JW; De Vivo DC; Kirschner J; Mercuri E; Muntoni F; Proud CM; Shieh PB; Tizzano EF; Quijano-Roy S; Desguerre I; Saito K; Faulkner E; Benguerba KM; Raju D; LaMarca N; Sun R; Anderson FA; Finkel RS
J Neuromuscul Dis; 2024; 11(2):425-442. PubMed ID: 38250783
[TBL] [Abstract][Full Text] [Related]
9. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1.
Bischof M; Lorenzi M; Lee J; Druyts E; Balijepalli C; Dabbous O
Curr Med Res Opin; 2021 Oct; 37(10):1719-1730. PubMed ID: 34236007
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacological and clinical profile of Onasemnogene Aveparvovec, the first gene therapy for spinal muscular atrophy (SMA)].
Atsumi A; Yoneda T; Tsuchida K; Kagawa Y; Tominaga S; Kawase K; Kikuchi N
Nihon Yakurigaku Zasshi; 2022; 157(1):53-61. PubMed ID: 34980814
[TBL] [Abstract][Full Text] [Related]
11. Onasemnogene abeparvovec for the treatment of spinal muscular atrophy.
McMillan HJ; Proud CM; Farrar MA; Alexander IE; Muntoni F; Servais L
Expert Opin Biol Ther; 2022 Sep; 22(9):1075-1090. PubMed ID: 35437095
[TBL] [Abstract][Full Text] [Related]
12. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.
Strauss KA; Farrar MA; Muntoni F; Saito K; Mendell JR; Servais L; McMillan HJ; Finkel RS; Swoboda KJ; Kwon JM; Zaidman CM; Chiriboga CA; Iannaccone ST; Krueger JM; Parsons JA; Shieh PB; Kavanagh S; Tauscher-Wisniewski S; McGill BE; Macek TA
Nat Med; 2022 Jul; 28(7):1381-1389. PubMed ID: 35715566
[TBL] [Abstract][Full Text] [Related]
13. Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular Atrophy.
René CA; Parks RJ
Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376212
[TBL] [Abstract][Full Text] [Related]
14. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O
Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305
[TBL] [Abstract][Full Text] [Related]
15. Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec -A Single Centre Experience.
Friese J; Geitmann S; Holzwarth D; Müller N; Sassen R; Baur U; Adler K; Kirschner J
J Neuromuscul Dis; 2021; 8(2):209-216. PubMed ID: 33427694
[TBL] [Abstract][Full Text] [Related]
16. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.
Strauss KA; Farrar MA; Muntoni F; Saito K; Mendell JR; Servais L; McMillan HJ; Finkel RS; Swoboda KJ; Kwon JM; Zaidman CM; Chiriboga CA; Iannaccone ST; Krueger JM; Parsons JA; Shieh PB; Kavanagh S; Wigderson M; Tauscher-Wisniewski S; McGill BE; Macek TA
Nat Med; 2022 Jul; 28(7):1390-1397. PubMed ID: 35715567
[TBL] [Abstract][Full Text] [Related]
17. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study.
Bitetti I; Lanzara V; Margiotta G; Varone A
Gene Ther; 2023 Aug; 30(7-8):592-597. PubMed ID: 35606491
[TBL] [Abstract][Full Text] [Related]
18. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy.
Mendell JR; Al-Zaidy SA; Lehman KJ; McColly M; Lowes LP; Alfano LN; Reash NF; Iammarino MA; Church KR; Kleyn A; Meriggioli MN; Shell R
JAMA Neurol; 2021 Jul; 78(7):834-841. PubMed ID: 33999158
[TBL] [Abstract][Full Text] [Related]
19. Continued safety and long-term effectiveness of onasemnogene abeparvovec in Ohio.
Waldrop MA; Chagat S; Storey M; Meyer A; Iammarino M; Reash N; Alfano L; Lowes L; Noritz G; Prochoroff A; Rossman I; Ginsberg M; Mosher K; Broomall E; Bass N; Gushue C; Kotha K; Paul G; Shell R; Tsao CY; Mendell JR; Connolly AM
Neuromuscul Disord; 2024 Jan; 34():41-48. PubMed ID: 38142474
[TBL] [Abstract][Full Text] [Related]
20. Gene transfer therapy in children with spinal muscular atrophy: A single-center experience with a cohort of 25 children.
Chencheri N; Alexander G; Nugud A; Majadas E; Salim H; Prudhomme K; DeJager N; Janardhanan VS; Elbashir H
Muscle Nerve; 2023 Sep; 68(3):269-277. PubMed ID: 37392188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]